Atossa Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATOS Nasdaq 2830 www.atossatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - Mar 11th, 2025 12:15 pm
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - Feb 5th, 2025 1:00 pm
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 - Jan 30th, 2025 1:17 pm
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - Jan 23rd, 2025 1:15 pm
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer - Jan 6th, 2025 2:00 pm
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Dec 20th, 2024 2:40 pm
Atossa Therapeutics to present poster on Z-endoxifen at SABCS - Dec 13th, 2024 1:20 pm
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - Dec 12th, 2024 1:15 pm
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - Dec 11th, 2024 1:15 pm
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - Dec 10th, 2024 2:05 pm
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - Dec 9th, 2024 1:15 pm
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - Nov 21st, 2024 1:30 pm
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - Nov 20th, 2024 1:30 pm
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year? - Nov 18th, 2024 2:40 pm
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 12th, 2024 1:30 pm
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - Nov 5th, 2024 1:30 pm
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: - Nov 4th, 2024 11:30 am
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - Oct 31st, 2024 12:15 pm
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Oct 28th, 2024 1:40 pm
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - Oct 21st, 2024 12:30 pm